Abstract:
Diabetic nephropathy is the leading cause of end-stage renal disease in the United States. Reninangiotensinaldosterone system (RAAS) blockers are thought to have a specific renoprotective effect in diabetes.
Hirst et al. report the results of randomized clinical trials assessing the effects of RAAS inhibitors on urinary albumin excretion levels in diabetic patients. Although reductions in urinary albumin excretion were observed, whether RAAS inhibitors offer additional protection over other antihypertensive agents is unclear.
This article is published in Kidney International: Kidney International (2012) 81, 615616; doi:10.1038/ki.2011.460
Or, click here to read the full article…
Kidney International (2012) 81, 615616; doi:10.1038/ki.2011.460
Additional Info
-
Language:
English -
Contains Audio:
No -
Content Type:
Articles -
Source:
KI -
Year:
2012 -
Members Only:
No